Private label Smoking Cessation Transdermal Patch

AmWiner raphegeneRics private label Nicotine smoking cessation transdermal patches. A pharmaceutical manufacturing plant with a yearly output of 3.7M packs per step using clinical research formulation. FDA-approved for Amazon, HEB, and Kroger as medical device transdermal drug delivery products. The preferred contract manufacturing pharmaceutical company for Perrigo and Johnson & Johnson specializes in transdermal drug delivery, minoxidil hair loss pills, oral and topical, and omeprazole gastric ulcer treatment. AmWiner Nicotine transdermal patch delivery system was the pioneer device at the clinical research conducted by A-Corp Palo Alto, California, University of California, San Francisco General Hospital, San Francisco, California and Marion Merrell Dow Inc., Kansas City, Missouri in the USA, and has since become the contract manufacturer of choice for A-Corp for Nicotine transdermal patches step 1 to 3. AmWiner formula has clinical research backup available upon contract.

AmWiner is a Generic drug manufacturer established in 2005, supplying over 150 generics over the counter to stores nationwide. AmWiner uses clinical trial formulas for every generic drug manufactured and provides clinical documents and finished product quality control test reports for each product. FDA cleared for 105 manufactured generic OTCs and two biologics for psoriasis treatment. AmWiner became the smoking cessation patch manufacturer of choice for drug stores in Canada in 2022, manufacturing each pack of step 1 through step 3 smoking cessation nicotine transdermal patches at $5.98.
AmWiner prepared a nicotine-loaded matrix by dissolving a polyether-type polyurethane in an appropriate solvent, adding liquid nicotine, and homogenizing the mixture. The matrix mixture is then cast onto the backing material using polymer casting techniques. After curing, a thin adhesive film is cast onto the matrix, or double-sided medical adhesive tape is attached. The release liner covers the adhesive, and patches of the desired size are cut out by punching. The finished patches are sealed into foil pouches and stored until needed.

Keywords: Private label nicotine smoking cessation transdermal patch, Nicoderm smoking cessation patch, Habitrol smoking cessation patch.

The patches of the present invention are preferably designed to replace one day's nicotine intake from cigarettes. The nicotine the patch releases during use is approximately 30 to 36 mg, with 68% to 76% of the released amount absorbed trans-dermally.

AmWiner specializes in Nicotine transdermal patches and oral solid dosage pills, both prescription and over-the-counter. They provide clinical studies for their smoking cessation transdermal patch formula, clinical research supporting step 1 smoking aid transdermal patches, and finished product testing validated by a third-party testing center for clinical trials.
Call 469-428-5508 for more details or send email to compounding@amwiner.com